Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2024

This “Complicated Skin and Soft Tissue Infections (c SSTI) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated Skin and Soft Tissue Infections (c SSTI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products inthisspace.

Geography Covered

• Global coverage

Complicated Skin and Soft Tissue Infections (c SSTI)Understanding

Complicated Skin and Soft Tissue Infections (c SSTI):Overview

Skin and soft tissue infections (SSTIs) refer to a wide clinical spectrum of common infectious diseases that often require acute treatment and inpatient hospital admission. Complicated SSTIs (c SSTIs) are the most severe, involving deeper soft tissues and include infective cellulitis, ulcer or wound site infections, surgical site infections, major abscesses, infected burns, skin ulcers, and diabetic foot ulcers. Staphylococcus aureus is the commonest cause of c SSTIs. The management of cSSTIs normally involves a combination of surgical procedures and antibiotic therapy. The main choice of antibiotic depends on theclinicalpresentation.

Complicated Skin and Soft Tissue Infections (c SSTI) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complicated Skin and Soft Tissue Infections (c SSTI) pipeline landscape is provided which includes the disease overview and Complicated Skin and Soft Tissue Infections (cSSTI) treatment guidelines. The assessment part of the report embraces, in depth Complicated Skin and Soft Tissue Infections (cSSTI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complicated Skin and Soft Tissue Infections (cSSTI) collaborations, licensing, mergers and acquisition, funding, designations and other productrelateddetails.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Skin and Soft Tissue Infections (c SSTI) R&D. The therapies under development are focused on novel approaches to treat/improve Complicated Skin and Soft Tissue Infections(cSSTI).

Complicated Skin and Soft Tissue Infections (c SSTI) Emerging DrugsChapters

This segment of the Complicated Skin and Soft Tissue Infections (c SSTI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and pressreleases.

Complicated Skin and Soft Tissue Infections (c SSTI) EmergingDrugs

Contezolid (MRX-I): MicuRx Pharmaceuticals Inc.Contezolid is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), while offering physicians and patients a safer and better tolerated therapeutic option than currently available oxazolidinone agents. The development of contezolid in China has been designated as a “Significant New Drugs Development Special Project,” and contezolid has also been granted QIDP designation and Fast Track status by the US FDA. The drug is in preregistration phase for treatment of cSSTI.

Ceftobiprole medocaril: Basilea Pharmaceutica Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp.3 The drug is currently approved and marketed in major European countries, Argentina, Canada, Jordan, Peru and Saudi Arabia for the treatment of adult patients with community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).3 Basilea has entered into license and distribution agreements for the brand in Europe, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) region. Ceftobiprole is currently in phase 3 clinical development for a potential registration in the U.S., with a completed study in acute bacterial skin and skin structure infections (ABSSSI) and an ongoing study in Staphylococcus aureus bacteremia(SAB).

Complicated Skin and Soft Tissue Infections (c SSTI): TherapeuticAssessment

This segment of the report provides insights about the different Complicated Skin and Soft Tissue Infections (c SSTI) drugs segregated based on following parameters that define the scope of the report, suchas:

Major Players in Complicated Skin and Soft Tissue Infections (cSSTI)

There are approx. 5+ key companies which are developing the therapies for Complicated Skin and Soft Tissue Infections (c SSTI). The companies which have their Complicated Skin and Soft Tissue Infections (c SSTI) drug candidates in the mid to advanced stage, i.e. phase III include, Baselia pharmaceuticaandothers.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Complicated Skin and Soft Tissue Infections (c SSTI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs suchas

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complicated Skin and Soft Tissue Infections (c SSTI): Pipeline DevelopmentActivities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complicated Skin and Soft Tissue Infections (c SSTI) therapeutic drugs key players involved in developing keydrugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complicated Skin and Soft Tissue Infections (c SSTI)drugs.

Complicated Skin and Soft Tissue Infections (c SSTI) ReportInsights

• Complicated Skin and Soft Tissue Infections (c SSTI) PipelineAnalysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Complicated Skin and Soft Tissue Infections (c SSTI) ReportAssessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Complicated Skin and Soft Tissue Infections (c SSTI)drugs?
• How many Complicated Skin and Soft Tissue Infections (c SSTI) drugs are developed by eachcompany?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complicated Skin and Soft Tissue Infections (cSSTI)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complicated Skin and Soft Tissue Infections (c SSTI)therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Complicated Skin and Soft Tissue Infections (c SSTI) and theirstatus?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MicuRx Pharmaceuticals Inc.
• Basilea pharmaceutica

Key Products

• MRX-I
• Ceftobiprole medocaril

This product will be delivered within 2 business days.